Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Regulus Therapeutics (RGLS) PT Raised to $1.37 at BMO Capital, Sees Shares 'Range-Bound'
March 8, 2018 5:52 AM ESTBMO Capital raised its price target on Regulus Therapeutics (NASDAQ: RGLS) to $1.37 (from $1.00) while maintaining a Market Perform rating.
"We believe investor focus will remain on the continued progress of Regulus's pipeline, particularly RG-012 for Alport syndrome where slower-than-expected enrollment and site... More
